DEFA14A: Recursion Pharmaceuticals Announces Change in Auditor, Board Chair Transition, and Director Withdrawal Ahead of Annual Meeting

Recursion Pharmaceuticals updates its proxy statement, announcing a change in its independent auditor from Ernst & Young LLP to PricewaterhouseCoopers LLP, the withdrawal of R. Martin Chavez as a nominee for Class III Director, and the election of Robert Hershberg as the new Chair of the Board.

Summary

• Recursion Pharmaceuticals has updated its proxy statement for the annual meeting of stockholders to be held on June 3, 2024.
• The company has appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm, effective upon completion of PwC's standard client acceptance process, and dismissed Ernst & Young LLP (EY) on May 7, 2024.
• An engagement letter was executed with PwC on May 22, 2024.
• R. Martin Chavez, Ph.D., Chair of the Board, has withdrawn his nomination for re-election as a Class III Director.
• Robert Hershberg, M.D., Ph.D. was elected as the Chair of the Board, effective at the Annual Meeting on May 23, 2024.
• The number of board members will be reduced from 9 to 8, effective at the Annual Meeting.
• The Board continues to recommend that stockholders vote FOR the election to the Board of each of the two nominees for Class III director: Blake Borgeson and Dean Y. Li.
• The Board also continues to recommend that stockholders vote FOR the approval, on an advisory basis, of the resolution approving the compensation of our Named Executive Officers as disclosed in the Proxy Statement.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The change in auditor and board leadership could be seen as positive, but the material weakness in internal control is a concern. Overall, the sentiment is neutral.

Positives

• The company has taken steps to remediate the material weakness in internal control over financial reporting.
• The company is transitioning to a new auditor, PwC, which may bring fresh perspectives and expertise.
• The appointment of Robert Hershberg as Chair of the Board may bring new leadership and strategic direction.

Negatives

• A material weakness existed in internal control over financial reporting for the year ended December 31, 2023.
• The company dismissed Ernst & Young LLP (EY) as their independent registered public accounting firm.
• R. Martin Chavez withdrew his nomination for re-election as a Class III Director.

Risks

• The transition to a new auditor, PwC, could present challenges in ensuring a smooth audit process.
• The material weakness in internal control over financial reporting could lead to further scrutiny from regulators or investors.
• The change in Board leadership could create uncertainty or disruption within the company.

Future Outlook

The company is focused on the upcoming Annual Meeting and the transition of leadership roles. They are also working to remediate the material weakness in internal control over financial reporting.

Management Comments

• The Board and Recursion's management wish to express their gratitude for Dr. Chavez's years of remarkable service to Recursion.

Industry Context

Changes in auditors and board leadership are common occurrences in publicly traded companies. The appointment of PwC aligns Recursion with a well-regarded accounting firm. The transition of board leadership reflects the evolving needs and priorities of the company.

Comparison to Industry Standards

• Switching auditors is not uncommon, and companies often do so after a period of years to gain a fresh perspective.
• Companies like Amgen and Gilead Sciences also use PwC as their auditor, indicating a preference for large, reputable firms in the biotech industry.
• Board leadership transitions are also typical, with companies like Pfizer and Merck undergoing similar changes in recent years.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders should be aware of the changes in auditor and board leadership when making voting decisions.
• Employees may experience changes in processes and procedures as a result of the new auditor.
• Customers and suppliers may not be directly impacted by these changes.

Next Steps

• Stockholders will vote on the election of directors and other proposals at the Annual Meeting on June 3, 2024.
• PwC will begin its engagement as the independent registered public accounting firm.
• The company will continue to remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Auditor, PricewaterhouseCoopers, Ernst & Young, Board of Directors, R. Martin Chavez, Robert Hershberg, Corporate Governance, Recursion Pharmaceuticals